CVD in patients with diabetes

Patient Care

Volumn 34, Issue 18, 2000, Pages 50-72

  Colwell, John ^a   Gerstein, Hertzel ^b   Zimmerman, Bruce ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2042518636     PISSN: 0031305X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Haffner SM, Lehto S. Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
2. Gress TW, Nieto J, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905-912.
3. Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med. 2000;160:1585-1594.
4. Devereux RB, Roman MJ, Paranicas M. Impact of diabetes on cardiac structure and function. The Strong Heart Study. Circulation. 2000;101: 2271-2276.
5. Steinberg HO, Paradisi G. Cronin J. et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation. 2000;101:2040-2046.
6. The BARI Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation [BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000;35:1122-1129.
7. King SB, Kosinksi AS, Guyton RA. et al. Eight-year mortality in the Emory Angioplasty Versus Surgery Trial [EAST). J Am Coll Cardiol. 2000;35: 1116-1121.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
9. Hansson L, Zanchetti A. Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment [HOT) randomised trial. Lancet 1998;351:1755-1762.
10. Tuomilehto J. Rastenyte D. Birkenhager WH. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
11. National Institutes of Health National Heart. Lung, and Blood Institute. The Sixth Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure [JNC VI). NIH publication 98-4080, November 1997.
12. Dinneen SF, Gerstein HC. The association of microalburninuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
13. American Diabetes Association. Position Statement Management of dyslipidemia in adults with diabetes. Diabetes Care. 2000;23(suppl1):S57-S60.
14. Rubins H. Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
15. Cook CB, Erdman DM, Ryan GJ, et al. The pattern of dyslipidemia among urban African Americans with type 2 diabetes mellitus. Diabetes Care. 2000;23:319-324.
16. American Diabetes Association. Position Statement Aspirin therapy in diabetes. Diabetes Care. 2000;23(suppl 1):S61-S62.
17. American Diabetes Association. Consensus Development Conference Report Consensus Development Conference on the Diagnosis of Coronary Heart Disease in People with Diabetes. Diabetes Care. 1998;21: 1551-1559.
18. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512-1515.